In addition, IL-2 has pleiotropic stimulatory effects by activating effector T cells and natural killers (NK) through the binding of the intermediate-affinity heterodimeric receptor IL-2Rβγ, but it also interacts with the high affinity heterotrimeric receptor complex IL-2Rαβγ promoting expansion of regulatory T cells (Tregs), which have known immune suppressive roles in the tumor microenvironment5–7. The gene discussed is IL2; the disease is neoplasm.